AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32903063 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 22
Study 32903063 — intervention group
Group type: COMPARATOR
Intervention: Various drugs
Number of subjects: 22
Study 32435057 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise programme of tailored aerobic and resistance training
Number of subjects: 131
Study 32435057 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 131
Study 33742252 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen (carboxy therapy + intralesional corticosteroids)
Number of subjects: 30
Study 33742252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroids (ILC)
Number of subjects: 30
Study 33742252 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxy therapy
Number of subjects: 30
Study 33710163 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 40
Study 32166395 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral subcostal transversus abdominis plane (TAP) block with 20 mL 0.25% bupivacaine
Number of subjects: 0
Study 32166395 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration at port sites with 20 mL 0.25% bupivacaine
Number of subjects: 0
Study 32166395 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 33941032 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led telemedicine counseling every 4 weeks
Number of subjects: 90
Study 33941032 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 90
Study 34133820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg every 8 hours for 5 days)
Number of subjects: 198
Study 34133820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (10 mg every 8 hours for 5 days)
Number of subjects: 198
Study 34133820 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg every 8 hours for 5 days)
Number of subjects: 198
Study 32909259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 119
Study 32909259 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study 35584930 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche of 9‐12 years
Number of subjects: 54937
Study 35584930 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche of 13 years
Number of subjects: 54937
Study 35584930 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche of 14 years
Number of subjects: 54937
Study 35584930 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche of 16 years
Number of subjects: 54937
Study 35584930 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche of 17 years
Number of subjects: 54937
Study 35584930 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche of 18‐20 years
Number of subjects: 54937
Study 35584930 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche of 40‐59 years
Number of subjects: 54937
Study 35584930 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche of 60‐79 years
Number of subjects: 54937
Study 35584930 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche of early age
Number of subjects: 54937
Study 34481881 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (a‐tDCS)
Number of subjects: 58
Study 34481881 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS (c‐tDCS)
Number of subjects: 58
Study 34481881 — intervention group
Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 58
Study 34479714 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed AWS
Number of subjects: 497819
Study 34479714 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not develop AWS
Number of subjects: 497819
Study 34479714 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for AWS
Number of subjects: 497819
Study 34479714 — intervention group
Group type: EXPERIMENTAL
Intervention: Model for predicting AWS
Number of subjects: 497819
Study 32093628 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 1978
Study 32093628 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 1978
Study 32093628 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg and 200 mg
Number of subjects: 1978
Study 33835089 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training
Number of subjects: 20
Study 33835089 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery only)
Number of subjects: 20
Study 34541612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib alone or following selective internal radiation therapy (SIRT)
Number of subjects: 312
Study 34541612 — intervention group
Group type: EXPERIMENTAL
Intervention: High gadoxetic acid uptake
Number of subjects: 312
Study 34541612 — intervention group
Group type: EXPERIMENTAL
Intervention: Child–Pugh class
Number of subjects: 312
Study 34541612 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor diameter
Number of subjects: 312
Study 34541612 — intervention group
Group type: EXPERIMENTAL
Intervention: ALBI grade
Number of subjects: 312
Study 33742323 — intervention group
Group type: EXPERIMENTAL
Intervention: PlasmaBlade® dissection
Number of subjects: 20
Study 33742323 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional electrocautery)
Number of subjects: 20
Study 33742323 — intervention group
Group type: EXPERIMENTAL
Intervention: PlasmaBlade® dissection and Control (traditional electrocautery)
Number of subjects: 20
Study 32716540 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline detergent immersion followed by multi-enzyme detergent ultrasonic cleaning
Number of subjects: 0
Study 32716540 — intervention group
Group type: COMPARATOR
Intervention: Other cleaning procedures (not specified)
Number of subjects: 0
Study 35290813 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (PPV)
Number of subjects: 1001
Study 35290813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1001
Study 32896644 — intervention group
Group type: EXPERIMENTAL
Intervention: one tDCS stimulation per day
Number of subjects: 93
Study 32896644 — intervention group
Group type: EXPERIMENTAL
Intervention: two tDCS stimulations per day
Number of subjects: 93
Study 32896644 — intervention group
Group type: COMPARATOR
Intervention: Sham group: one sham tDCS stimulation per day
Number of subjects: 93
Study 32896644 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (Group I and II)
Number of subjects: 93
Study 35220556 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 35220556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33861441 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg) and famotidine (40 mg) daily for 1 month
Number of subjects: 75
Study 33861441 — intervention group
Group type: COMPARATOR
Intervention: Placebo and famotidine (40 mg)
Number of subjects: 75
Study 37434220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittently scanned continuous glucose monitor (isCGM) (FreestyleLibre2)
Number of subjects: 0
Study 37434220 — intervention group
Group type: COMPARATOR
Intervention: Self-monitored blood glucose (SMBG)
Number of subjects: 0
Study 37434220 — intervention group
Group type: EXPERIMENTAL
Intervention: isCGM
Number of subjects: 0
Study 37434220 — intervention group
Group type: COMPARATOR
Intervention: isCGM and SMBG
Number of subjects: 0
Study 34813645 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 14
Study 34813645 — intervention group
Group type: COMPARATOR
Intervention: Demineralized bone xenograft (DMBM)
Number of subjects: 14
Study 33270945 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phenylalanine/tyrosine depletion in the LFS group
Number of subjects: 31
Study 33270945 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phenylalanine/tyrosine depletion in both diet groups
Number of subjects: 31
Study 33270945 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline peripheral dopamine precursor availability (pDAP) in the HFS group
Number of subjects: 31
Study 34782918 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based random forest model
Number of subjects: 286
Study 32702699 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous alteplase
Number of subjects: 2526
Study 32702699 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose intravenous alteplase
Number of subjects: 2526
Study 32702699 — intervention group
Group type: EXPERIMENTAL
Intervention: Background features of brain frailty (atrophy, white matter change, old infarcts)
Number of subjects: 2526
Study 616702026 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training program using free weights (FW)
Number of subjects: 62
Study 616702026 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training program using elastic tubing (ET)
Number of subjects: 62
Study 616702026 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 62
Study 36910899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal local anesthesia with 20 mL of heated (40°C) 2% lidocaine gel (n = 50)
Number of subjects: 100
Study 36910899 — intervention group
Group type: COMPARATOR
Intervention: Periprostatic nerve block (PNB) (n = 50)
Number of subjects: 100
Study 33394849 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct health education by phone calls
Number of subjects: 560
Study 33394849 — intervention group
Group type: COMPARATOR
Intervention: No phone call (control group)
Number of subjects: 560
Study 33394849 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone call group
Number of subjects: 560
Study 33394849 — intervention group
Group type: EXPERIMENTAL
Intervention: Young FDRs
Number of subjects: 560
Study 33394849 — intervention group
Group type: EXPERIMENTAL
Intervention: FDRs living within 200 km of the hospital
Number of subjects: 560
Study 33394849 — intervention group
Group type: EXPERIMENTAL
Intervention: Probands with moderate to severe visual impairment
Number of subjects: 560
Study 34404334 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal help-seeking behaviors (HSBs)
Number of subjects: 390
Study 34404334 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal HSB
Number of subjects: 390
Study 34404334 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal HSB
Number of subjects: 390
Study 34635066 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 50
Study 34635066 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 50
Study 32838982 — intervention group
Group type: EXPERIMENTAL
Intervention: esketamine/SNP
Number of subjects: 20
Study 32838982 — intervention group
Group type: COMPARATOR
Intervention: esketamine/placebo
Number of subjects: 20
Study 32838982 — intervention group
Group type: EXPERIMENTAL
Intervention: racemic ketamine/SNP
Number of subjects: 20
Study 32838982 — intervention group
Group type: COMPARATOR
Intervention: racemic ketamine/placebo
Number of subjects: 20
Study 33334936 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance use to participants and HCPs (n=87)
Number of subjects: 437
Study 33334936 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance use to participants (n=88)
Number of subjects: 437
Study 33334936 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance and rescue use to participants and HCPs (n=88)
Number of subjects: 437
Study 33334936 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance and rescue use to participants (n=88)
Number of subjects: 437
Study 33334936 — intervention group
Group type: COMPARATOR
Intervention: No feedback (control) (n=86)
Number of subjects: 437
Study 33334936 — intervention group
Group type: EXPERIMENTAL
Intervention: Data on rescue use
Number of subjects: 437
Study 33334936 — intervention group
Group type: EXPERIMENTAL
Intervention: All study arms
Number of subjects: 437
Study 35058418 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel fitting algorithm
Number of subjects: 103
Study 35058418 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (optometrist's calculation)
Number of subjects: 103
Study 33080088 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 2859
Study 33080088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2859
Study 35835616 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH)
Number of subjects: 3
Study 33933916 — intervention group
Group type: EXPERIMENTAL
Intervention: BVDV antibody competitive-ELISA assay
Number of subjects: 339
Study 33933916 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 339
Study 35442901 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiking neural networks (SNNs) with a double recurrent network imitating the hippocampus
Number of subjects: 0
Study 35442901 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellum-inspired module for radial contact response
Number of subjects: 0
Study 35442901 — intervention group
Group type: EXPERIMENTAL
Intervention: Block-based feedforward network for movement planning
Number of subjects: 0
Study 35442901 — intervention group
Group type: EXPERIMENTAL
Intervention: Controller and planner for generating teaching signals
Number of subjects: 0
Study 34358819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 40
Study 34358819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 35803469 — intervention group
Group type: EXPERIMENTAL
Intervention: Camostat mesylate 300 mg three times daily in a fasted state
Number of subjects: 90
Study 35803469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 35803469 — intervention group
Group type: EXPERIMENTAL
Intervention: Camostat mesylate
Number of subjects: 90
Study 32828877 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity eye drops
Number of subjects: 80
Study 32828877 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-viscosity eye drops
Number of subjects: 80
Study 32828877 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 80
Study 32738206 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training program (supervised training) from 3rd to 6th months after surgery
Number of subjects: 58
Study 32738206 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 58
Study 32738206 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training program
Number of subjects: 58
Study 35482790 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Transfusion (BT, n = 24)
Number of subjects: 48
Study 35482790 — intervention group
Group type: COMPARATOR
Intervention: Control (CON, n = 24)
Number of subjects: 48
Study 33914570 — intervention group
Group type: EXPERIMENTAL
Intervention: MST‐PSB
Number of subjects: 48
Study 33914570 — intervention group
Group type: COMPARATOR
Intervention: UCS
Number of subjects: 48
Study 33180187 — intervention group
Group type: EXPERIMENTAL
Intervention: Retained urinary catheter (UC)
Number of subjects: 230
Study 33180187 — intervention group
Group type: COMPARATOR
Intervention: Non-retained urinary catheter (non-UC)
Number of subjects: 230
Study 34393696 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclophosphamide + fish oil
Number of subjects: 237
Study 34393696 — intervention group
Group type: COMPARATOR
Intervention: cyclophosphamide + placebo
Number of subjects: 237
Study 33840359 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric conditioning activity (3 sets of 5 countermovement jumps)
Number of subjects: 14
Study 32229229 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical training (PT) group, n = 22, received home‐based supervised muscle strength and endurance training in twice‐weekly 60‐min sessions for 12 weeks
Number of subjects: 44
Study 32229229 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical training (PT) group, n = 22
Number of subjects: 44
Study 32229229 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised activity booklet group, n = 22
Number of subjects: 44
Study 33554565 — intervention group
Group type: EXPERIMENTAL
Intervention: AI autoverification system
Number of subjects: 0
Study 33554565 — intervention group
Group type: COMPARATOR
Intervention: Rule-based engine
Number of subjects: 0
Study 34498207 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid EVD wean protocol
Number of subjects: 0
Study 34498207 — intervention group
Group type: COMPARATOR
Intervention: Gradual EVD wean protocol
Number of subjects: 0
Study 32285983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated frequency-doubled 1064/532 nm picosecond Nd:YAG laser (FPL)
Number of subjects: 20
Study 32285983 — intervention group
Group type: COMPARATOR
Intervention: Fractionated 1927 nm thulium fiber laser (TFL)
Number of subjects: 20
Study 35267491 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 + bevacizumab (arm A)
Number of subjects: 65
Study 35267491 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI + bevacizumab (arm B)
Number of subjects: 65
Study 35267491 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pathological response (PR) among all CRLMs
Number of subjects: 65
Study 35351723 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at time of peak hyperglycaemia (ExPeak, personalised)
Number of subjects: 70
Study 35351723 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise not at time of peak hyperglycaemia (NonPeak)
Number of subjects: 70
Study 35351723 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC, standard care)
Number of subjects: 70
Study 33536190 — intervention group
Group type: EXPERIMENTAL
Intervention: PI3Kβ inhibitor AZD8186
Number of subjects: 0
Study 33536190 — intervention group
Group type: EXPERIMENTAL
Intervention: AKT inhibitor MK-2206
Number of subjects: 0
Study 33536190 — intervention group
Group type: EXPERIMENTAL
Intervention: MEK inhibitor selumetinib
Number of subjects: 0
Study 33536190 — intervention group
Group type: COMPARATOR
Intervention: selumetinib (clinical trial)
Number of subjects: 0
Study 32928788 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 0
Study 32928788 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 35852576 — intervention group
Group type: EXPERIMENTAL
Intervention: SoC+CT
Number of subjects: 862
Study 35852576 — intervention group
Group type: COMPARATOR
Intervention: SoC
Number of subjects: 862
Study 33367691 — intervention group
Group type: EXPERIMENTAL
Intervention: teen Mental Health First Aid (teenMHFA) program
Number of subjects: 979
Study 34978662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid decision support system using Artificial Intelligence for low-risk prescriptions
Number of subjects: 420
Study 34978662 — intervention group
Group type: COMPARATOR
Intervention: High-risk prescriptions
Number of subjects: 420
Study 34978662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid decision support system
Number of subjects: 420
Study 34978662 — intervention group
Group type: COMPARATOR
Intervention: Clinical Decision Support System (CDSS)
Number of subjects: 420
Study 34978662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid decision support tool
Number of subjects: 420
Study 34195574 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg per day)
Number of subjects: 795
Study 34195574 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib (150 mg per day)
Number of subjects: 795
Study 35705502 — intervention group
Group type: EXPERIMENTAL
Intervention: DIZ101 (intravenous infusion of levodopa/carbidopa)
Number of subjects: 20
Study 35705502 — intervention group
Group type: EXPERIMENTAL
Intervention: DIZ102 (subcutaneous infusion of levodopa/carbidopa)
Number of subjects: 20
Study 35705502 — intervention group
Group type: COMPARATOR
Intervention: LCIG (intestinal infusion of levodopa/carbidopa)
Number of subjects: 20
Study 35705502 — intervention group
Group type: EXPERIMENTAL
Intervention: DIZ102
Number of subjects: 20
Study 35705502 — intervention group
Group type: EXPERIMENTAL
Intervention: DIZ101 and DIZ102
Number of subjects: 20
Study 35705502 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (DIZ101, DIZ102, LCIG)
Number of subjects: 20
Study 32108898 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Polymyxin™ NP (RP‐NP) for CRE
Number of subjects: 163
Study 32108898 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Polymyxin™ Acinetobacter (RP‐AB) for CRAB
Number of subjects: 163
Study 32108898 — intervention group
Group type: COMPARATOR
Intervention: Broth microdilution (BMD)
Number of subjects: 163
Study 35475975 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) decoction, administered twice a day for at least 3 and up to 24 months.
Number of subjects: 338
Study 34266456 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte and platelet-rich fibrin (L-PRF) applied on ulcer beds during twice-weekly dressing changes
Number of subjects: 130
Study 34266456 — intervention group
Group type: COMPARATOR
Intervention: Usual care (saline dressings only) during twice-weekly dressing changes
Number of subjects: 130
Study 35266830 — intervention group
Group type: EXPERIMENTAL
Intervention: hNB001 (20 mg to 400 mg)
Number of subjects: 0
Study 35266830 — intervention group
Group type: EXPERIMENTAL
Intervention: hNB001
Number of subjects: 0
Study 35266830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32824214 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich dietary pattern for eight weeks
Number of subjects: 0
Study 32824214 — intervention group
Group type: COMPARATOR
Intervention: Control diet for eight weeks
Number of subjects: 0
Study 34559684 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil therapy (3% concentration)
Number of subjects: 0
Study 34559684 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mineral oil without essential oil)
Number of subjects: 0
Study 32101065 — intervention group
Group type: EXPERIMENTAL
Intervention: LC+BDE (Laparoscopic Choledochotomy with Primary Closure)
Number of subjects: 207
Study 32101065 — intervention group
Group type: COMPARATOR
Intervention: LC+ESE (Laparoscopic Cholecystectomy combined with Endoscopic Stone Extraction)
Number of subjects: 207
Study 32101065 — intervention group
Group type: EXPERIMENTAL
Intervention: LC+BDE
Number of subjects: 207